Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic renal cell carcinoma
- 31 December 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (9) , 1313-1315
- https://doi.org/10.1016/0959-8049(93)90080-y
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaEuropean Journal Of Cancer, 1992
- Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.Journal of Clinical Oncology, 1992
- Long-term results in patients with metastatic renal cell carcinoma treated with interferon with or without vinblastineWorld Journal of Urology, 1991
- Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.Journal of Clinical Oncology, 1990
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Interferon treatment of renal cell carcinoma. Current status and future prospectsCancer, 1987
- Reporting results of cancer treatmentCancer, 1981